Introduction
vinca alkaloids and, during exposure to higher levels of drugs, mitotic spindles deteriorate as a result of altered tubulin dynamics [19] . Among different vinca alkaloid derivatives, vinorelbine was a third generation drug selected for development; this molecule has shown markedly improved clinical efficacy and is the least toxic [20] . The actions of vinorelbine on the mitotic spindle may constitute only one aspect of its cytotoxic action, as it has also been shown to modulate receptor binding of epidermal growth factor to breast cancer cells with potential consequences for cell viability [21] .
In our study, a novel drug combination consisting of a cytotoxic agent (vinorelbine) with a recombinant mouse monoclonal antibody against human VEGF (2C3) has been evaluated for the treatment of metastatic RCC. We have chosen two cell lines: the highly malignant A498 cells and the lesser malignant 786-O cells for in vitro and in vivo study. Both of these cell lines are VHL-negative. As a control, the VHL-positive Caki1 cell line was used to check the effect of vinorelbine on in vitro cell viability. The results obtained justify preclinical studies to evaluate the effectiveness of a combined therapy using vinorelbine and 2C3 as a potential treatment for RCC.

Materials and methods
Reagents
Drugs: Vinorelbine is available from Gensia Sicor Pharmaceuticals, Inc. (Irvine, CA, USA); and the anti-VEGF antibody 2C3 is a mouse monoclonal antibody developed to target human VEGF, as described previously [22] . Control antibody (IgG) 
was purchased from Peregrine Pharmaceuticals (TX, USA). Anticaspase-3 (#9662), caspase-8 (#9746), caspase-9 (#9502), anti-Cyclin A (#4656), p-mTOR (#2971), mTOR (#2972) antibodies were purchased from
In vitro cell growth inhibition assay
Results
Inhibition of cell growth
The anti-proliferative effect of vinorelbine against different human cell lines has already been established [23] [24] [25] . To verify its effect on renal cancer cell growth, A498 and 786-O cells were treated with increasing concentrations of vinorelbine (10 nM, 100 nM, and 1M) and cell survival was assessed with the MTT assay. As shown in Fig. 1 
, survival was inversely correlated with drug concentration. Significant loss of A498 and 786-O viability was detected at 100 and 10 nM of vinorelbine, respectively, in a dosedependent manner (Fig. 1, P Ͻ 0.01 compared to untreated cells). In Caki1 RCC cells, 10 nM of vinorelbine treatment caused significant growth inhibition after only 24 hrs of treatment (Fig. S1).
Effect on cell cycle
Regulators of cell cycle phase transitions could be important targets for cancer treatment using cytostatic chemotherapy. There are several reports describing the effect of vinca alkaloids on cell cycle phase perturbations and on vinorelbine treatment causing general G2/M phase arrest [24, 26] . Cell cycle analysis with different concentrations of vinorelbine treatments in A498 cells is shown in Fig. 2A . Fig. 2A) .
A 100 nM concentration of vinorelbine led to increases in both the G2/M (P Ͻ 0.01) as well as S-phase (P Ͻ 0.01) fractions, whereas only a 10 nM dose caused significant G2/M arrest in 786-O cells (P Ͻ 0.01). There was also a moderate increase in the S-phase fraction of 786-O cells after a 10 nM vinorelbine treatment (
Effect of vinorelbine on Cyclin A, Cyclin B1, Cdk1, p-histone H3 and PCNA expression
Cell cycle is the orchestrated series of molecular events. Progression through successive stages of cell cycle is accompanied by the altered expression and lack of expression of specific regulatory proteins. Cyclin B1, expressed in the G2/early M phase of the cell cycle [27] , and Cyclin A seem to be required for both the S and M phases [28] [27] . In both cell lines, the level of histone H3 phosphorylation progressively increased in a dose-dependent manner after treatment with vinorelbine (Fig. 2B) . The G2/M transition is triggered by the regulation of the Cyclin B1-Cdk1 complex, which promotes the breakdown of the nuclear membrane, chromatin condensation and microtubule spindle formation [29] . Immunoblotting revealed that vinorelbine drug treatment resulted in a significant induction of Cdk1 protein levels but not in PCNA expression. caspase-3 activation in leukaemia and lymphoma cells [31] . We found that a 100 nM dose was sufficient for the induction of activated capase-3 and -9 activity in A498 cells after 72 hrs treatment (Fig. 4C) . A 48-hr vinorelbine treatment of 100 nM in 786-O cells caused little increase in both caspase-3 and caspase-9, but a significant increase was detected with a 1.0 M dose (Fig. 4C) (Fig. 5A) . In A498 renal carcinoma, the combination therapy also significantly improved the response compared to the single 2C3 therapy (P ϭ 0.031) (Fig. 5A) (Fig. 5B) . Fig. 6A and B (Fig. 7A) .
Effect of vinorelbine on cell invasion
Invasion of tumour cells through the matrix of the microenvironment is an early process of metastasis. It was reported that exposure to vinorelbine inhibits in vitro invasiveness of transitional cell bladder carcinoma [23]. To determine whether vinorelbine plays an inhibitory role in the invasion of renal cancer cells, we performed a Matrigel invasion assay in the presence or absence of the drug. Figure 3 shows a 10 nM dose of vinorelbine was sufficient to inhibit the invasion of both A498 and 786-O cells (P Ͻ 0.01).
Effect of vinorelbine on cell apoptosis
A therapeutic approach will most likely require a drug-mediated induction of apoptotic activity on the cancer cell. Figure 4A describes apoptosis measurement using Annexin/PI. We observed a dose-dependent induction of apoptosis in A498 and 786-O cells after vinorelbine treatment. A 100 nM dose of the drug induced significant apoptosis in A498 cells, whereas in 786-O cells only a 10 nM dose of vinorelbine was sufficient to induce marked apoptosis. No induction in apoptosis was observed when treating with 2C3 (data not shown).
Effect of vinorelbine on Akt and mTOR phosphorylation
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Fig. 2 In vitro effect of vinorelbine on A498 and 786-O cell cycle regulation and cell cycle protein expression. (A) Three different doses of vinorelbine were used to assess the effect of vinorelbine on cell cycle regulation in A498 and 786-O cells. At a 100 nM dose, a significant G2/M phase arrest (P Ͻ 0.01 compared to untreated cells) was observed in A498, whereas 786-O cells arrested at the G2/M phase with a 10 nM dose of vinorelbine. **, P Ͻ 0.01(treated group versus control group). (B) When A498 and 786-O cells were treated with vinorelbine for 72 hrs and 48 hrs, respectively, increased Cyclin B1, phospho-histone H3, and Cdk1 were detected with doses of 100 nM and 10 nM of vinorelbine in A498 and 786-O tumours cells, respectively. In both cell lines, Cyclin
Effect of vinorelbine in combination with anti-vascular endothelial growth factor antibody 2C3 on PCNA expression in vivo
To determine whether the observed tumour growth suppression was caused by inhibition of cell proliferation, we investigated the effect of vinorelbine alone and in combination with 2C3 on tumour cell proliferation as measured by proliferating cell nuclear antigen (PCNA) (
Effect of vinorelbine in combination with anti-vascular endothelial growth factor antibody 2C3 on tumour angiogenesis
In our next step, we were interested to determine the effect of vinorelbine alone and in combination with 2C3 on tumour angiogenesis. Therefore, we stained tumour sections from the A498 renal cancer model with anti-vWF antibody ( Fig. 8A and B (Fig. 8A ).
Discussion
The management of RCC has constituted a therapeutic challenge and no standard therapy has been established until now. [32] . Though several treatment strategies have been investigated for RCC, the best therapeutic option is yet to be discovered. [33] [34] [35] [36] .
Conventional clear cell RCC comprises two-thirds of renal masses and has a less favourable outcome compared to papillary RCC and chromophobe RCC
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Fig. 3 Effect of vinorelbine on A498 and 786-O invasion in vitro. The effect of vinorelbine on A498 and 786-O cells invasion was assayed after 24 hrs of treatment. A 10 nM dose of vinorelbine was sufficient to inhibit both A498 and 786-O cells invasion after 6 hrs (P Ͻ 0.01 compared to untreated cells). The values represent an average of three separate experiments. **, P Ͻ 0.01 (treated group versus control group).
Vinca alkaloids are a very important class of drugs used for the treatment of different cancers. Of these, vinblastine, vincristine, vindesine and vinflunine have been used either singly or in combination with other drugs in different phases of clinical trials for patients with advanced RCC
Vinorelbine, a semi-synthetic vinca alkaloid with a broad spectrum of anti-tumour activity, has been used as a single agent in inoperable or advanced non-small cell lung cancer (NSCLC) and was also found to be effective in slowing metastasis in advanced breast cancer as a first liner or later chemotherapy [37] . Vinorelbine has also emerged as a therapeutic option for breast cancer chemotherapy during pregnancy with a very favourable toxicity profile [38] . It was reported that the combination of vinorelbine and trastuzumab for the treatment of metastatic breast cancer was effective and well tolerated [39] . Despite broadspectrum use of vinorelbine in the management of different cancers, there are very few reports on the use of vinorelbine for the treatment of metastatic RCC [40] . [41] . However, because vinorelbine induces cell arrest by inhibiting the G2/M [42, 43] . It is an FDA-approved drug, which has shown efficacy in both the first and second line stages of Phase II clinical trials with metastatic RCC [44] . Bevacizumab has also demonstrated clinical activity in metastatic RCC in other Phase II trials [45, 46] 
